Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Launched by NOVARTIS PHARMACEUTICALS · Apr 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at new treatments for people with moderate to severe atopic dermatitis, which is a chronic skin condition that causes itchy and inflamed skin. The trial aims to test several investigational compounds to see if they are effective and safe for patients. It is not yet recruiting participants, but when it does, it will include individuals aged 6 to 75 who have been diagnosed with atopic dermatitis for at least a year.

To participate, individuals must be willing to sign an informed consent form and have moderate to severe symptoms of atopic dermatitis. However, those with certain medical conditions, such as serious infections, uncontrolled diabetes, or other skin diseases, may not be eligible. Participants can expect to receive treatment and will be monitored throughout the study to ensure their safety. This trial is an important step in finding better options for managing atopic dermatitis, which can significantly impact a person's quality of life.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria of the master protocol:
• • Able and willing to sign the informed consent (IC)
• • Patients with a diagnosis of AD and onset of disease for at least 1 year
• • Moderate to severe AD
• Key Exclusion Criteria of the master protocol:
• • Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
• • Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
• • Participant with any other active inflammatory skin disease
• • Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
• • Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
• • Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements